{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:39:03Z","timestamp":1792543143617,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lung adenocarcinoma (LUAD), the most common subtype of lung cancer, is associated with substantial global mortality. Nuclear receptor coactivator 5 (NCOA5) has been implicated in several malignancies; however, its functional role and regulatory mechanisms in LUAD remain largely unknown. In this study, NCOA5 expression was evaluated in 94 paired LUAD and adjacent tissues using immunohistochemistry, RT-PCR, and Western blotting. Functional analyses were conducted using shRNA knockdown, CRISPR-mediated knockout, and overexpression models to assess the effects of NCOA5 on LUAD cell proliferation, migration, invasion, apoptosis, cell cycle progression, and organoid formation. Xenograft models were used to validate tumorigenicity in vivo. IP-MS and co-immunoprecipitation identified NCOA5-interacting proteins, while ChIP-seq and dual-luciferase assays interrogated downstream transcriptional regulation. NCOA5 was significantly upregulated in LUAD tissues and associated with advanced stage, poor differentiation, and reduced overall survival, serving as an independent prognostic factor (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u2009.040). NCOA5 knockdown inhibited LUAD cell proliferation, migration, invasion, induced G0\/G1 arrest, promoted apoptosis, reduced organoid formation, and suppressed xenograft growth, whereas NCOA5 overexpression produced the opposite effects. Among 39 candidate interacting proteins identified by IP-MS, ZCCHC3 was validated as a direct NCOA5-binding partner. ZCCHC3 depletion phenocopied NCOA5 loss and reversed NCOA5-induced proliferation, migration, invasion, and colony formation, supporting a functional NCOA5\u2013ZCCHC3 interaction. ChIP-seq analysis identified fibroblast growth factor 22 (FGF22) as a direct transcriptional target of NCOA5. FGF22 was markedly downregulated in LUAD tissues and higher FGF22 expression was associated with improved patient survival. NCOA5 suppressed FGF22 transcription, while NCOA5 inhibition increased FGF22 expression. Functionally, FGF22 knockdown enhanced LUAD aggressiveness, whereas FGF22 restoration abrogated the oncogenic effects of NCOA5 in vitro and in vivo. Collectively, these findings identify a previously unrecognized NCOA5\u2013ZCCHC3\/FGF22 axis that drives LUAD progression and provide new mechanistic insight into the role of NCOA5 in LUAD biology.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09127-9","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:02:56Z","timestamp":1784937776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and validation of NCOA5-ZCCHC3\/FGF22 axis as a prognostic marker in lung adenocarcinoma migration and invasion"],"prefix":"10.1038","volume":"17","author":[{"given":"Yiran","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdun","family":"Chaogetu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-4390","authenticated-orcid":false,"given":"Rila","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"9127_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"9127_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"9127_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109742","volume":"27","author":"L Zha","year":"2024","unstructured":"Zha L, Matsu-Ura T, Sluka JP, Murakawa T, Tsuta K. Morphological basis of the lung adenocarcinoma subtypes. iScience. 2024;27:109742.","journal-title":"iScience"},{"key":"9127_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"9127_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJJ, Wu Y, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299\u2013311.","journal-title":"Lancet"},{"key":"9127_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"M Meyer","year":"2024","unstructured":"Meyer M, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404:803\u201322.","journal-title":"Lancet"},{"key":"9127_CR7","doi-asserted-by":"publisher","first-page":"e0247620","DOI":"10.1371\/journal.pone.0247620","volume":"16","author":"H Burnett","year":"2021","unstructured":"Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLoS One. 2021;16:e0247620.","journal-title":"PLoS One"},{"key":"9127_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1128\/MCB.21.1.343-353.2001","volume":"21","author":"F Sauv\u00e9","year":"2001","unstructured":"Sauv\u00e9 F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Gigu\u00e8re V. CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. 2001;21:343\u201353.","journal-title":"Mol Cell Biol"},{"key":"9127_CR9","doi-asserted-by":"publisher","first-page":"27781","DOI":"10.1074\/jbc.M401809200","volume":"279","author":"C Jiang","year":"2004","unstructured":"Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H. TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem. 2004;279:27781\u20139.","journal-title":"J Biol Chem"},{"key":"9127_CR10","first-page":"106","volume":"3","author":"CY Liu","year":"2014","unstructured":"Liu CY, Feng G. NCOA5, a molecular link between type 2 diabetes and liver cancer. Hepatobiliary Surg Nutr. 2014;3:106\u20138.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"9127_CR11","doi-asserted-by":"publisher","first-page":"15525","DOI":"10.1038\/s41598-019-52105-9","volume":"9","author":"S Gao","year":"2019","unstructured":"Gao S, Zhang Y, Yang C, Perez GI, Xiao H. NCOA5 Haplo-insufficiency Results in Male Mouse Infertility through Increased IL-6 Expression in the Epididymis. Sci Rep. 2019;9:15525\u20139.","journal-title":"Sci Rep"},{"key":"9127_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cmet.2013.12.010","volume":"19","author":"D Dhar","year":"2014","unstructured":"Dhar D, Seki E, Karin M. NCOA5, IL-6, type 2 diabetes, and HCC: The deadly quartet. Cell Metab. 2014;19:6\u20137.","journal-title":"Cell Metab"},{"key":"9127_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bbrc.2018.04.017","volume":"500","author":"J He","year":"2018","unstructured":"He J, Zhang W, Li A, Chen F, Luo R. Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 2018;500:177\u201383.","journal-title":"Biochem Biophys Res Commun"},{"key":"9127_CR14","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1038\/s41388-020-1256-x","volume":"39","author":"M Williams","year":"2020","unstructured":"Williams M, Liu X, Zhang Y, Reske J, Bahal D, Gohl TG, et al. NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21(WAF1\/CIP1) overexpression, which is reversed by metformin. Oncogene. 2020;39:3821\u201336.","journal-title":"Oncogene"},{"key":"9127_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2017.01.028","volume":"391","author":"X Liu","year":"2017","unstructured":"Liu X, Liu F, Gao S, Reske J, Li A, Wu C, et al. A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation. Cancer Lett. 2017;391:152\u201361.","journal-title":"Cancer Lett"},{"key":"9127_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/CAD.0000000000001759","volume":"36","author":"H Zhou","year":"2025","unstructured":"Zhou H, Zhang Q, Yang L, Pan Z, Zheng H, Zhang Z, et al. Inhibition of nuclear receptor coactivator 5 overcomes acquired lenvatinib resistance driven by protein kinase B-mammalian target of rapamycin signaling in hepatocellular carcinoma. Anticancer Drugs. 2025;36:779\u201387.","journal-title":"Anticancer Drugs"},{"key":"9127_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jcmgh.2023.10.010","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Feng G. NCOA5 deficiency in macrophages provokes NASH and HCC. Cell Mol Gastroenterol Hepatol. 2024;17:171\u20132.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"9127_CR18","doi-asserted-by":"publisher","first-page":"113157","DOI":"10.1016\/j.celrep.2023.113157","volume":"42","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Liu X, Sun K, Luo Y, Yang J, Li A, et al. Hyperpolarization-activated cyclic nucleotide-gated cation channel 3 promotes HCC development in a female-biased manner. Cell Rep. 2023;42:113157.","journal-title":"Cell Rep"},{"key":"9127_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/OTT.S154158","volume":"11","author":"Z Zheng","year":"2018","unstructured":"Zheng Z, Wang Q, Zhang W, Zhang X, Huang D. A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma. Onco Targets Ther. 2018;11:307\u201311.","journal-title":"Onco Targets Ther"},{"key":"9127_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0376-y","volume":"31","author":"G Chen","year":"2014","unstructured":"Chen G, Tian H, Yue W, Li L, Li S, Qi L, et al. NCOA5 low expression correlates with survival in esophageal squamous cell carcinoma. Med Oncol. 2014;31:376.","journal-title":"Med Oncol"},{"key":"9127_CR21","first-page":"1888","volume":"15","author":"Y Wu","year":"2018","unstructured":"Wu Y, Wu J, Dong Q, Guo N. Association between expression of nuclear receptor co-activator 5 protein and prognosis in postoperative patients with osteosarcoma. Oncol Lett. 2018;15:1888\u201392.","journal-title":"Oncol Lett"},{"key":"9127_CR22","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1002\/jcb.27911","volume":"120","author":"Y Liang","year":"2019","unstructured":"Liang Y, Zhang T, Shi M, Zhang S, Guo Y, Gao J, et al. Low expression of NCOA5 predicts poor prognosis in human cervical cancer and promotes proliferation, migration, and invasion of cervical cancer cell lines by regulating notch3 signaling pathway. J Cell Biochem. 2019;120:6237\u201349.","journal-title":"J Cell Biochem"},{"key":"9127_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbrc.2016.11.051","volume":"482","author":"X Ye","year":"2017","unstructured":"Ye X, Huang D, Luo R. NCOA5 is correlated with progression and prognosis in luminal breast cancer. Biochem Biophys Res Commun. 2017;482:253\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"9127_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3892\/ol.2021.12955","volume":"22","author":"Y Tan","year":"2021","unstructured":"Tan Y, Liu F, Xu P. Knockdown of NCOA5 suppresses viability, migration and epithelial-mesenchymal transition, and induces adhesion of breast cancer cells. Oncol Lett. 2021;22:694.","journal-title":"Oncol Lett"},{"key":"9127_CR25","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.2174\/1871520621666210126093630","volume":"21","author":"E Xia","year":"2021","unstructured":"Xia E, Hu W, Bhandari A, Sindan N, Huang D. Nuclear Receptor Coactivator 5 is Correlated with Progression in Breast Carcinoma. Anticancer Agents Med Chem. 2021;21:2520\u20134.","journal-title":"Anticancer Agents Med Chem"},{"key":"9127_CR26","doi-asserted-by":"publisher","first-page":"1117033","DOI":"10.3389\/fonc.2023.1117033","volume":"13","author":"X Song","year":"2023","unstructured":"Song X, Qian D, Dai P, Li Q, Xi Q, Sun K. Expression and clinical significance of NCOA5 in epithelial ovarian cancer. Front Oncol. 2023;13:1117033.","journal-title":"Front Oncol"},{"key":"9127_CR27","doi-asserted-by":"publisher","first-page":"107932","DOI":"10.18632\/oncotarget.22429","volume":"8","author":"K Sun","year":"2017","unstructured":"Sun K, Wang S, He J, Xie Y, He Y, Wang Z, et al. NCOA5 promotes proliferation, migration and invasion of colorectal cancer cells via activation of PI3K\/AKT pathway. Oncotarget. 2017;8:107932\u201346.","journal-title":"Oncotarget"},{"key":"9127_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0063-y","volume":"9","author":"TV Denisenko","year":"2018","unstructured":"Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9:117.","journal-title":"Cell Death Dis"},{"key":"9127_CR29","unstructured":"Who. Lung cancer. World Health Organization. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer."},{"key":"9127_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1158\/1078-0432.CCR-13-0731","volume":"20","author":"PM Forde","year":"2014","unstructured":"Forde PM, Kelly RJ, Brahmer JR. New strategies in lung cancer: translating immunotherapy into clinical practice. Clin Cancer Res. 2014;20:1067\u201373.","journal-title":"Clin Cancer Res"},{"key":"9127_CR31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288\u2013300.","journal-title":"Transl Lung Cancer Res"},{"key":"9127_CR32","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jhep.2025.11.017","volume":"84","author":"X Cheng","year":"2026","unstructured":"Cheng X, Xia Y, Li C, Zhang M, Inuzuka T, Chakka S, et al. A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection. J Hepatol. 2026;84:874\u201386.","journal-title":"J Hepatol"},{"key":"9127_CR33","doi-asserted-by":"publisher","first-page":"150663","DOI":"10.1016\/j.bbrc.2024.150663","volume":"735","author":"A Fujimoto","year":"2024","unstructured":"Fujimoto A, Ikeda K, Takeiwa T, Osaki A, Horie K, Inoue S. ZCCHC3 and Efp coordinately contribute to the pathophysiology of triple-negative breast cancer by modulating NCAPH. Biochem Biophys Res Commun. 2024;735:150663.","journal-title":"Biochem Biophys Res Commun"},{"key":"9127_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100335","volume":"26","author":"L Wang","year":"2020","unstructured":"Wang L. ELF1-activated FOXD3-AS1 promotes the migration, invasion and EMT of osteosarcoma cells via sponging miR-296-5p to upregulate ZCCHC3. J Bone Oncol. 2020;26:100335.","journal-title":"J Bone Oncol"},{"key":"9127_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.immuni.2018.08.014","volume":"49","author":"H Lian","year":"2018","unstructured":"Lian H, Zang R, Wei J, Ye W, Hu M, Chen Y, et al. The zinc-finger protein ZCCHC3 binds RNA and facilitates viral RNA sensing and activation of the RIG-I-like receptors. Immunity. 2018;49:438\u2013448.e5.","journal-title":"Immunity"},{"key":"9127_CR36","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1007\/s00018-020-03518-7","volume":"77","author":"U Aceituno-Valenzuela","year":"2020","unstructured":"Aceituno-Valenzuela U, Micol-Ponce R, Ponce MR. Genome-wide analysis of CCHC-type zinc finger (ZCCHC) proteins in yeast, Arabidopsis, and humans. Cell Mol Life Sci. 2020;77:3991\u20134014.","journal-title":"Cell Mol Life Sci"},{"key":"9127_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116\u201329.","journal-title":"Nat Rev Cancer"},{"key":"9127_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF\/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5:181.","journal-title":"Signal Transduct Target Ther"},{"key":"9127_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215\u201366.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"9127_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3892\/ol.2022.13555","volume":"24","author":"Y Chen","year":"2022","unstructured":"Chen Y, Liu X, Yang L, He J, Jiang Y, Mai J. Systematic analysis of expression profiles and prognostic significance of the FGF gene family in pancreatic adenocarcinoma. Oncol Lett. 2022;24:435.","journal-title":"Oncol Lett"},{"key":"9127_CR41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/abbs\/gmab074","volume":"53","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Qin Y, Ji S, Xu W, Liu M, Hu Q, et al. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22\/FGFR2 promotes invasion and metastasis of pancreatic cancer. Acta Biochim Biophys Sin. 2021;53:997\u20131008.","journal-title":"Acta Biochim Biophys Sin"},{"key":"9127_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3892\/ol.2024.14450","volume":"28","author":"K Zhao","year":"2024","unstructured":"Zhao K, Xu J, Zhao B. Panoramic RNA expression of fibroblast growth factors in human glioblastoma tissues and the impact on the survival of patients. Oncol Lett. 2024;28:317.","journal-title":"Oncol Lett"},{"key":"9127_CR43","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3892\/ijo.2014.2718","volume":"46","author":"T Suzuki","year":"2015","unstructured":"Suzuki T, Yasuda H, Funaishi K, Arai D, Ishioka K, Ohgino K, et al. Multiple roles of extracellular fibroblast growth factors in lung cancer cells. Int J Oncol. 2015;46:423\u20139.","journal-title":"Int J Oncol"},{"key":"9127_CR44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12943-024-02167-9","volume":"23","author":"M Peng","year":"2024","unstructured":"Peng M, Deng J, Li X. Clinical advances and challenges in targeting FGF\/FGFR signaling in lung cancer. Mol Cancer. 2024;23:256\u20139.","journal-title":"Mol Cancer"},{"key":"9127_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.diff.2025.100860","volume":"143","author":"R Furuta","year":"2025","unstructured":"Furuta R, Miyake A. Fibroblast growth factor 22. Differentiation. 2025;143:100860.","journal-title":"Differentiation"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09127-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09127-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09127-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:09:01Z","timestamp":1792541341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09127-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9127"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09127-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations. Patient samples were obtained from Inner Mongolia People\u2019s Hospital, and all human experiments were approved by the Ethics Committee of Inner Mongolia Autonomous Region People\u2019s Hospital (Approval No. 202517610\u2009K). All participants\/donors signed the informed consent form.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"896"}}